Clover : Results of 2020 CLV Annual General Meeting
November 20, 2020 at 12:25 am EST
Share
Clover Corporation Limited
ABN 85 003 622 866
ASX ANNOUNCEMENT
20 November 2020
The Manager
Company Announcements Office ASX limited
20 Bridge Street SYDNEY NSW 2000
2020 ANNUAL GENERAL MEETING - RESULTS OF MEETING
Following are the results of resolutions put to the Shareholders of the Company at the Annual General Meeting held Friday 20 November:
Item 2 - To adopt the Remuneration Report for the year ended 31 July 2020.
Carried
Item 3 - To re‐elect Mr I Glasson as a Director of the Company.
Carried.
Item 4 - To elect Dr S Green as a Director of the Company.
Carried
Item 5 - To elect Ms T Brendish as a Director of the Company.
Carried
Item 6 - To approve variation of FY20 performance rights granted to Managing Director
Carried
Item 7 - To approve variation of FY21 performance rights granted to Managing Director
Carried
Item 8 - To approve Managing Director leaving benefit due to early vesting of FY20 & FY21 performance rights
Carried
In accordance with Listing Rule 3.13.2 and Section 251AA(2) of the Corporations Act 2001 details of the proxies received for the meeting are attached.
Signed for and on behalf of Clover Corporation Ltd
Paul Sherman
Company Secretary
CLOVER CORPORATION LIMITED
2020 Annual General Meeting
Friday, 20 November 2020
Results of Meeting
The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
Resolution details
Resolution
Resolution
Type
1
Adoption of remuneration report
Ordinary
2
Re-election of Mr Ian Glasson as a director
Ordinary
3
Election of Dr Simon Green as a director
Ordinary
4
Election of Ms Toni Brendish as a director
Ordinary
5
Approval of variation of FY20 performance rights
Ordinary
6
Approval of acquisition of FY21 performance rights
Ordinary
7
Approval of Managing Directors leaving benefit
Ordinary
Instructions given to validly appointed proxies
(as at proxy close)
For
Against
Proxy's
Abstain
Discretion
79,604,557
1,164,663
606,100
193,322
97.83%
1.43%
0.74%
80,503,472
554,364
657,100
164,139
98.52%
0.68%
0.80%
80,508,972
554,864
621,100
194,139
98.56%
0.68%
0.76%
80,454,651
604,223
626,996
193,205
98.50%
0.74%
0.76%
79,658,362
1,123,528
592,800
504,385
97.90%
1.38%
0.72%
79,735,493
1,046,383
592,800
504,399
98.00%
1.28%
0.72%
68,586,117
12,167,528
594,800
530,630
84.32%
14.95%
0.73%
Number of votes cast on the poll
(where applicable)
For
Against
Abstain*
81,315,657
1,164,663
193,322
98.59%
1.41%
82,265,572
554,364
164,139
99.33%
0.67%
82,235,072
554,864
194,139
99.33%
0.67%
82,186,647
604,223
193,205
99.27%
0.73%
81,281,162
1,198,528
504,385
98.55%
1.45%
81,383,293
1,096,383
504,399
98.67%
1.33%
70,210,917
12,242,528
530,630
85.15%
14.85%
Resolution
Result
Carried /
Not Carried
Carried
Carried
Carried
Carried
Carried
Carried
Carried
* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
Clover Corporation Limited published this content on 20 November 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 November 2020 05:24:01 UTC
Clover Corporation Limited is focused on technology, new product development and commercialization. The principal activities of the Company are the refining and sale of natural oils, the production of encapsulated powders and the research and product development of functional food and infant nutrition ingredients. The Companyâs microencapsulation technology enables nutritional oils, such as tuna, fish, algal and fungal oils, to be added to infant formula, foods, and beverages. Its technologies protect those sensitive oils from oxidation, allowing them to be incorporated into a range of applications. The Company, through its subsidiary, Nu-Mega Ingredients Pty Limited (Nu-Mega), supplies refined Omega-3 oils and a range of other encapsulated ingredients for use in infant formula, nutraceuticals, pharmaceuticals, and sports nutrition markets. Nu-Megaâs Driphorm range of microencapsulated powders enables the addition of Hi-DHA tuna and/or algal oils to a broad spectrum of products.
CLOVER CORPORATION LIMITED 
